XTalks

JANUARY 22, 2025

Valneva SE, who developed the worlds first FDA-approved chikungunya vaccine , has now unveiled promising Phase III data for its single-shot chikungunya vaccine, IXCHIQ, in adolescents aged 12 to 17. The study included 754 adolescents, comparing immune responses and safety profiles between vaccine and placebo groups.

Immune Response 59

Immune Response Vaccine Vaccination Trials 59

XTalks

NOVEMBER 5, 2024

Additionally, a collaboration with NurExone is creating an intranasal delivery system for exosome-based therapies targeting spinal cord injuries, with potential expansion into other neurological uses. Polyrizon’s focus on intranasal protection aligns with a rapidly expanding market in drug delivery innovation.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

Pharmaceutical Technology

APRIL 24, 2023

Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages. However, after a period of slow movement in the field, the FDA approved the first nanodrug, Doxil, for Kaposi sarcoma in 1995.

Drug Delivery 147

Drug Delivery Vaccine Vaccination Research 147

XTalks

NOVEMBER 3, 2021

In this episode, Ayesha discusses the FDA’s authorization of Pfizer/BioNTech’s COVID-19 vaccine for children between five and 11 years of age. The team also learned about the FDA approval of Genentech’s new ocular implant drug delivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD).

Life Science 52

Life Science Drug Delivery Systems Vaccine Vaccination 52

The Pharma Data

OCTOBER 26, 2020

EYSUVIS is the first FDA-approved corticosteroid specifically for dry eye disease treatment. Kala’s proprietary AMPPLIFY drug delivery technology is what gets EYSUVIS its backstage pass to penetrate the mucus barrier and delivering the loteprednol etabonate (LE) to the ocular tissue. INVELTYS launched in the U.S.

FDA Approval 52

FDA Approval Immune Response Drug Delivery Drugs 52

XTalks

MAY 30, 2024

CIDP is a rare autoimmune disorder where the body’s immune system mistakenly attacks its own tissues. The exact cause of this immune response is unknown, and there appears to be no identifiable genetic predisposition to CIDP. In early 2021, the FDA approved Pfizer’s Panzyga for the treatment of CIDP.

FDA Approval 40

FDA Approval Immune Response Trials Drug Delivery 40